Skip to main content

Liquidia

Liquidia Corporation is an American clinical and commercial-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative therapeutic medicines utilizing its proprietary PRINT (Particle Replication in Non-Wetting Templates) precision particle engineering technology platform to design engineered medicines with precise size, shape, and composition, prominently featuring Yutrepia (treprostinil) designed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company conducts advanced clinical research in pulmonary medicine. Its core business operations encompass precision particle drug engineering, clinical-stage drug development, pharmaceutical manufacturing, and commercial medical affairs. Revenue is derived primarily from commercial product sales of approved specialized respiratory therapeutics and biopharmaceutical licensing agreements. Liquidia holds a leading market position in precision particle engineering and pulmonary hypertension treatments. The company is headquartered in Morrisville, North Carolina, United States, and its common stock trades on the Nasdaq Global Market under the ticker LQDA.

2 of the funds FundTelligence covers report a position in Liquidia.

Legal name
Liquidia Corp
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Liquidia

Loading...